NDAORALFOR SUSPENSION
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPECTROBID (bacampicillin hydrochloride) is an oral aminopenicillin antibiotic approved in 1982 for bacterial infections. It is a prodrug of ampicillin that provides improved oral bioavailability. The drug treats susceptible gram-positive and gram-negative bacterial infections via beta-lactam cell wall inhibition.
LOE Approaching
Product approaching loss of exclusivity with minimal current spending data suggests a mature, declining franchise with small team focus on transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SPECTROBID represents a legacy brand in transition with minimal active job openings and limited career growth potential. Career opportunities center on managing LOE, optimizing generic transition, or supporting continuity in established markets rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on SPECTROBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.